15\p=n-\100 times lower than the normal rate; hexahydrogenated cortolones a and \ g=b\ were found to be 7\ x =r eq-\ to 20-fold lower than normal levels; and the 11-keto-17-ketosteroid derivatives of cortisone were also reduced. Urinary elimination of the cortisol-reduced metabolites 5\g=b\-and 5\g=a\-tetrahydrogenated cortisol were slightly reduced or normal. These results argue in favor of a deficit in the enzyme 11\g=b\-HSD,which oxidizes cortisol into cortisone. A moderate defect in the conversion of cortisol into 5\g=b\-THFcompared to normal conversion into 5\g=a\-THFwas also found. With respect to corticosterone metabolism, we demonstrated the presence of a defect in the oxidation of that steroid into dehydrocorticosterone, also due to the deficit in 11\g=b\-HSD,Arterial hypertension and hypokalemia were corrected by treatment with dexamethasone, concomitantly with correction of the low aldosterone and plasma renin activity levels. On the other hand, during this treatment, urinary concentrations of the metabolites of cortisol. cortisone and corticosterone were only moderately affected.
The syndrome of apparent mineralocorticoid excess type 1 (AME 1) is a rare cause of low-renin juvenile arterial hypertension due to an anomaly of oxidation of cortisol to cortisone (1) (2) . The discovery of the mineralocorticoid action of cortisol (3) expressed at the site of the mineralocorticoid receptor (4) explains why, in the absence of oxidation of cortisol to inactive cortisone by 11/3-hydroxysteroid dehydrogenase , the renal tubule is exposed to large quantities of "mineralocorticoid" unmetabolized cortisol, resulting in hypermineralocorticism and hypertension.
While the mechanism of this hypertension is now understood, the metabolic anomalies described in subjects presenting congenital 11/3-HSD deficits are not unambiguous (5) . fn addition, the effects obtained by treatment aimed at reducing cortisol production may be interpreted in various ways.
In this paper we report our observations concerning two brothers with an 11/3-HSD deficit in whom glucocorticoids, mineralocorticoids and the major urinary metabolites of these were studied, and whose hypertension was clearly improved by dexamethasone (DXM) administration. After these purification, hydrolysis, extraction and repurification steps, the steroids were transformed into methyloxime-trimethylsilyl ethers (10) (11) (12) The 17-ketosteroid metabolites of cortisol , 11/3-OHandrosterone and 11/9-OH-etiocholanolone, were excreted at normal rates, whereas the corresponding 11-keto metabolites of cortisone were reduced, resulting in an increase in the 11/3-OH-androsterone +H/3-OHetiocholanolone/11-ketoandrosterone + 11-ketoetiocholanolone ratio (Table 2 ).
Materials and methods

Patients
Mineralocorticoid metabolites. The rates of elimination of the tetrahydrogenated derivatives of 5/3-THB and of 5a-THB were below normal or only slightly reduced, whereas the tetrahydrogenated derivatives of 11-dehydrocorticosterone (THA) were heavily reduced (Table 2) , the 5/3-THB+5q-THB/THA ratio being higher than the uppermost normal value.
Discussion
The very rare AME 1 syndrome is associated with severe, occasionally precocious, arterial hypertension and constant hypokalemia. The renin-angiotensinaldosterone axis is totally blocked, while the plasma DOC level is normal. Blockage of the mineralocorticoid receptor by spironolactone leads to a decrease in arterial blood pressure, which we observed in patient no. 1. A deficit in the enzyme 11/3-HSD2, which respectively converts cortisol and corticosterone into both hormonally inactive cortisone and dehydrocorticosterone has been demonstrated (13) . More recently it has been shown that this enzyme was co-localized with the mineralocorticoid receptor in aldosterone target cells, especially in the distal tubule and in the renal col¬ lecting duct (14) . In normal physiology it prevents the mineralocorticoid receptor from permanent occupancy by cortisol, which is in much higher concentrations in plasma than is aldosterone and for which the miner¬ alocorticoid receptor displays the same affinity as for the latter.
In these brothers a diagnosis of AME was initially hypothesized on the basis of plasma assays. The demonstration of 11/3-HSD enzyme deficiency was later established on the basis of urine assays. Indeed, we found a low elimination rate of THE (with a strong increase in the 5/3-THF+5a-THF/THE ratio), of the hexahydrogenated derivatives of cortisone (a-and ß-cortolone) and ofthe 17-ketosteroids 11-ketoandrosterone and 11-ketoetiocholanolone compared with the 11-hydroxylated derivatives. We found also reduced levels of THA coupled with an increase in the 5/3-THB + 5a-THB/THA ratio, indicating that 11/3-HSD enzyme deficiency is associated with a failure of inactivation of corticosterone into 11-dehydrocorticosterone conse¬ quently contributing to a small extent to the apparent hypermineralocorticism.
As described by Ulick et al. (15) , in both types of AME (1 and 2) the decrease in metabolism of cortisol into 5/3-THF and 5a-THF here is moderate and essentially affects the reduction of the cortisol A ring by 5/3-reductase into 5/3-THF. The UFF remains normal or increased (patient no. 2); consequently, the 5/3-THF+5 a-THF/UFF ratio is decreased. In Table 3 
